/PRNewswire/ Idoven, a pioneering health tech company advancing early detection and precision medicine of cardiovascular disease, today announced that it.
Clene Reports Second Quarter 2021 Operating and Financial Highlights biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Published: May 17, 2021
International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease
Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis
SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE)
Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, received a Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine (NAM) to accelerate the preclinical development of CNM-Au8, a bioenergetic nanocatalyst, for treatment of neuronal aging-related deficits and Alzheimer’s disease. The Healthy Longevity Global Competition was founded in 2019